Nanoviricides, Inc. (NYSE: NNVC), an SEC filer in Pharmaceutical Preparations, closed at $1.24, -3.1%, on 2026-08-28, with a market cap of $28M as of 2026-08-27 and a return on equity of -99.7%. Institutional ownership, earnings history and filed financials are on the tabs below.
| Size & multiples | |||
| Market Cap (close × cover-page shares) | $26.8M | Enterprise Value | — |
| P/E (TTM) | — | PEG (trailing) | — |
| P/S | — | P/FCF | — |
| EV/EBITDA | — | EV/EBIT | — |
| EV/Sales | — | EV/FCF | — |
| FCF Yield | −27.46% | Buyback Yield | — |
| Owner Earnings Yield | — | Shareholder Yield | — |
| Cost of capital & EVAmethodology → | |||
| Beta (5y monthly) | 1.69 | Risk-free (assumed) | 4.00% |
| Equity risk premium (assumed) | 4.23% | Cost of Equity | — |
| After-tax Cost of Debt | — | WACC | — |
| ROIC | — | EVA Spread (ROIC−WACC) | — |
| EVA | — | ||
Flows TTM (last 4 quarters); latest annual for: EPS (Diluted), Revenue, Interest Expense · EPS TTM -$0.63 · revenue TTM $0 · FCF TTM -$7.4M
Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.
Loading the monthly cohort placement…
Whole-sector pool — median skews small.
| Metric | This (FY) | Peer median | IQR (25–75) | %ile |
|---|---|---|---|---|
| FCF Yield | -30.8% | -7.0% | -31.8%–1.5% | 25 ↓weak |
| ROE | -99.7% | -36.9% | -92.5%–4.5% | 23 ↓weak |
This company's industry pool year publishes once its group is tagged, its annual revenue is stored and the newest year clears the filing-alignment guard. A coverage gap, never a statement about the company.
Held-with peers…
Peers by disclosure language…
